key: cord-0788952-3ykn4v82
authors: Pieri, Marina; Donatelli, Vittoria; Calabrò, Maria Grazia; Scandroglio, Anna Mara; Pappalardo, Federico; Zangrillo, Alberto
title: Eleven years of VV ECMO for ARDS: from H1N1 to SARS-COV-2. Experience and perspectives of a national referral center
date: 2021-09-24
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2021.09.029
sha: 39cc5b0a444d08480553b921827fda0f31c8b47d
doc_id: 788952
cord_uid: 3ykn4v82

Objective Despite growing expertise and wide application of venovenous extracorporeal membrane oxygenation (VV ECMO) treatment for acute respiratory distress syndrome (ARDS) of different origin and during pandemics (H1N1 Influenza A virus and SARS-CoV2), large reports are few and pertain mostly to multicentre registries, while randomized trials are difficult to perform. The aim of this study was to report outcomes, trends and innovations of VV ECMO treatment over the last eleven years. Design, setting and participants Observational study on 142 patients treated at the IRCCS San Raffaele Hospital in Milan from June 2009 (year of the H1N1 pandemic) to May 2020 (SARS-CoV-2 pandemic). Interventions None. Measurements and main results The main causes of ARDS were H1N1 pneumonia in 36% of patients, bacterial pneumonia in 17% and Sars-CoV-2 in 9%. Seventy-two percent of patients were centralized from remote hospitals, of which 33% had implanted VV ECMO before transport. The most common cannulation strategy was the dual lumen catheter cannulation system (55%) and anticoagulation was performed with bivalirudin in most patients (79%). Refractory hypoxia was treated with iv beta-blockers (64%), nitric oxide (20%) and pronation (8%). Almost one third of patients (32%) were extubated while on ECMO. Forty-nine percent of patients were discharged from intensive care unit and hospital discharge was 46%: survival was lower in patients requiring VV ECMO for more than 3 weeks compared to lower support duration (23% vs 56%, p=0.007). Anticoagulation with bivalirudin was associated with higher survival compared to heparin (55% vs 31%, p=0.03) and lower thrombocytopenia incidence (69% vs 35%, p=0.003). Conclusion VV ECMO is the pivotal rescue treatment for refractory ARDS: timely treatment and optimal care are needed to optimize therapy, since duration of support is associated with outcome. Anticoagulation with bivalirudin may improve outcome.

Acute Respiratory Distress Syndrome (ARDS) is a severe clinical manifestation of heterogeneous origin that is still burdened with high mortality (up to 65%, with great variability among casistics) [1, 2] . Over the last two decades the therapy of this syndrome has evolved significantly, in particular with the temporary replacement of lung function by venovenous extracorporeal membrane oxygenation (VV ECMO) in patients refractory to conventional ventilation technique [1, 3] .

Despite high initial mortality rate [3, 4] , interest in VV ECMO has continuously increased following technical and clinical progresses, and it represented a fundamental rescue therapy even during H1N1 influenza A pandemic [5, 6] and SARS-CoV-2 pandemic. The use of such an invasive and demanding therapy in critically ill patients requires high expertise level, 24/7 availability and optimal clinical management [7] . To date, VV ECMO effects on survival remain however controversial compared to conventional mechanical ventilation and no definitive survival benefits has been demonstrated in randomized trials. Randomized trials are nevertheless difficult to implement due to complicated ethical and logistical issues [8, 9] . A recent systematic review of the literature analysed data from 33 studies with more than 100 VV ECMO patients (32 observational studies and one randomized controlled trial: despite the great amount of data (12860 patients), however, most information come from international registries that collected not contemporary data [2] . Furthermore, the number of patients treated in each centre was limited, and data reported in 4 different studies were few and not consistent, making comparison of patients' population and management very difficult.

The aim of this study was to report outcomes, trends and innovations in the management of VV ECMO treatment in a large population of patients treated over the last eleven years in a national referral center.

All adult patients treated with VV ECMO due to refractory ARDS at IRCCS San Raffaele Scientific Institute in Milan from June 2009 to May 2020 were included in the study.

Criteria for VV ECMO treatment eligibility and exclusion criteria have been previously reported and were consistent over years [10] . In case of refractory hypoxia in ARDS patients, physicians in remote hospital were put in connection with the ECMO center via national phone number: an ECMO specialist was available for case discussion in order to optimize therapy and decide whether to centralize the patient to the referral center [11] . VV ECMO was implanted by the ECMO team either before or after transport to the referral center. The decision to implant VV ECMO before transport was undertaken by the ECMO team in case of patients deemed at immediate risk of death and too ill and hypoxic to be transferred without extracorporeal support [11] . We performed percutaneous cannulation with Seldinger technique: since 2012 our first line preferred approach was with bilumen cannula, as alternative to femoro-jugular or femoro-femoral approach [11] . Cause of ARDS were classified as follows: H1N1 Influenza A virus; bacterial pneumonia, other viral pathogens other than Influenza A (including Influenza B and Sars-CoV-2 virus), other causes (including medical causes of ARDS such as pancreatitis, post-surgical ARDS as in case of abdominal surgery, polytrauma, sepsis of undetermined origin, autoimmune disease,..). All patients were administered intravenous (iv) anticoagulation to achieve target activated partial thromboplastin time of 55-60 seconds: primary anticoagulation was performed with heparin until 5 2011 and with the direct thrombin inhibitor bivalirudin from 2011 to present [12] [13] [14] . Sequential Organ Failure Assessment (SOFA) Score, Simplified Acute Acute Physiology Score (SAPS), Acute Physiology And Chronic Health Evaluation (APACHE) II and III scores and the VV ECMO specific ECMOnet score [15] were calculated. Hemorrhagic complications were recorded according to the ELSO definitions. Major bleeding was defined as: clinically bleeding with a decrease in hemoglobin of at least 2 g/dl/24 h; a transfusion requirement of 1 or more 10 ml/kg red blood cells transfusions over 24 h; retroperitoneal bleeding, pulmonary or bleedings that involved the central nervous system or required surgical intervention [16] .

Right ventricular failure secondary to ARDS was treated with iv inotropes, nitric oxide and, if needed, intraaortic balloon pump (IABP) [17] .

Refractory hypoxia in spite of VV ECMO (60-80 ml/kg/min) was managed nitric oxide and pronation and, since 2011 with intravenous short-acting beta blockers administration [18, 19] . More in details, a continuous infusion of esmolol was to administer in case of persisting severe hypoxemia (peripheral O2 saturation <91% or PaO2/FIO2 <100 mmHg despite ECMO treatment) and concomitant high cardiac output (>7 L/min) as measured by pulmonary artery catheter, and titrated to an SpO2 > 92% [18] . Data were collected from patients' medical records and anonymously stored in an Excel Database at the IRCCS San Raffaele Hospital. The study is in compliance with the Declaration of Helsinki and data were collected with the approval of our local ethical committee.

Categorical variables are reported as numbers (percentage), whereas continuous variables are expressed as mean ± standard deviation (SD) or as median (interquartile range) according to the Kolmogorov-Smirnov test.

6 One hundred and forty-two patients were treated in the study period (June 2009 -May 2020).

Baseline data are shown in table 1: 93 were men (65%), mean age was 54±14 years and BMI 28±7.

The main causes of ARDS were: H1N1 pneumonia in 36% of patients, bacterial pneumonia in 16%, and Sars-CoV-2 infection in 9% of patients. The main comorbidities were obesity (23%) and immunodepression (9.2%) (table 1). Baseline PaO 2 /FiO 2 was 64 (52 -77):. Patients had high mortality risk according to risk scores: SOFA was 12 ± 5, SAPS II was 66 ± 25; APACHE II was 28 (22-35), APACHE III was 103 ± 54 and the ECMOnet score 7 ± 4. Variations of pre ECMO respiratory parameters and cause of ARDS over the years under study are shown in supplementary figure 1 and 2, respectively.

As shown in Table 2 , 93/129 patients (72%) were referred to the San Raffaele Hospital from another facility, and among these 31/93 (33%) were implanted VV ECMO before transport because they were considered at immediate risk of death if transferred without extracorporeal support.

Notably, no cannulation related issues were recorded. Median duration of VV ECMO treatment was 9 (5-18) days with a maximum of 75 days. The cannulation system was the dual lumen jugular cannula in 71/129 cases (55%), the femoro-jugular in 57/129 (44%) and the femoro-femoral in only 1/129 patient (1%).

Therapeutic management is shown in table 3. Patients received intravenous anticoagulation with unfractionated heparin until 2011 (26/125, 21%) and bivalirudin later on (99/125, 79%). Half of the patients had need for support to the circulatory system with inotropes after ECMO implantation (65/129, 50%) and 25/129 patients (20%) also needed concomitant mechanical circulatory support with IABP. In 47/129 patients (36%) continuous venous hemofiltration (CVVH) was used while the use of Cytosorb for blood purification was applied in 19/129 patients (15%).

Most patients (82/129, 64%) received iv beta-blocker continuous infusion due to refractory hypoxia despite VV ECMO support; therapy with nitric oxide (NO) was administered to 26/129 patients 7 (20%) and 10/129 patients were proned (8%) Moreover, 20/129 patients (15%) received platelet transfusions due to severe thrombocytopenia. Overall 73 circuit exchanges were performed: 37 (51%) due to oxygenator signs of impaired performance or failure and 36 (49%) due to activation of coagulation with the aim to prevent bleeding episodes.

Thirty-two percent of patients (41/129) underwent extubation during VV ECMO support ("awake ECMO") and 45/129 patients (35%) had tracheostomy. Mobilization was an essential part of ECMO patients' management strategies: 32/129 patients (25%) were mobilized on one side and 19/129 in the armchair (15%) ( Table 4) .

Complications are reported in table 5. Notably, no major complication related to cannulation procedure was recorded. Sepsis was recorded in 44/129 patients (34%), multi-organ failure (MOF) in 39/129 patients (30%) and major bleeding was registered in 28/129 patients (22%) Sixty-three percent of patients (82/129 patients) were weaned from ECMO, 49% (67/137 patients) were discharged from the intensive care unit (ICU) and 63/137 (46%) were discharged from hospital. A trend toward increase in ICU survival rate over the years under study was observed, as shown in supplementary figure 3. Overall, patients were admitted to ICU for 16 (32-9) days while in hospital for an overall duration of 23 (38-14) days (Table 5) . No baseline single parameter was found to be associated with outcome; patients who needed VV ECMO support for more than 3 weeks had lower survival rate compared to patients who had VV ECMO treatment shorter than 3 weeks (23% vs 56% , p=0.007).

8 Patients who received anticoagulation with bivalirudin had higher survival rate compared to patients treated with heparin (ICU survival 55% vs 31%, p=0.03). In addition, incidence of thrombocytopenia with platelet count < 50000 per blood microliter during treatment was almost doubled in patients treated with heparin compared to bivalirudin (69% vs 35%, p=0.003)(supplementary table 1). A trend toward high ICU survival was recorded also in patients treated with beta blockers compared to controls (53% vs 41% p=0.2) and in case of adoption of bilumen cannulation strategy compared to other strategies (53% vs 43% p=0.3), although these findings were not statistically significant. Outcome according to the cause of ARDS is reported in supplementary figure 4. The recurrence of pandemic events over decades, together with technological and clinical advances has led to a rapid increase in the number of patients undergoing VV ECMO support, together with a consequent increase in centres capable of managing ECMO treatment, with particular reference to adult patients. In this regard, our study documented that we were able to deal with complex scenarios over years, such as pandemic outbreaks, and to manage even very critically ill patients with high predicted mortality risk. The overall results of the study indicate that VV ECMO is applicable to patients in ARDS with different aetiologies and that, despite the still numerous complications often associated with it, 63% of patients recovered from ARDS and were weaned from ECMO and, in 49% of cases, discharged from ICU.

From the data collected, it can be seen that VV ECMO is still burdened by various complications, mainly sepsis, MOF and hemorragic complications. However, as already highlighted in the past, it is complicated to determine whether the occurrence of such events can be reduced by improving ECMO or supportive therapy, or whether they are simply a consequence of the critical conditions of patients treated with ECMO [20] . Therefore, it should be underlined the need for further dedicated studies to define its origin. Finally, it should be remembered that VV ECMO treatment still remains significantly invasive and applied in patients who, by definition, are severely compromised. In the light of these considerations, it seems logical that the next efforts towards reducing adverse events and complications will be particularly challenging. At our institution, for this reason, we implemented some strategies over years with the aim to improve management and ultimately outcomes of the patients. More in details, we focused on anticoagulation therapy (with the use of direct thrombin inhibitors for systemic anticoagulation) [12] [13] [14] , on coupling hemodynamics and oxygenation (administering i.v short half-life beta-blockers during VV ECMO) [18, 19] , and on less invasive cannulation strategies ( after the availability of bilumen jugular cannula).

During ECMO treatment, haemostasis modifications are complex and can cause both haemorrhagic and thrombotic events due to numerous alterations of the coagulative cascade. Contact of the blood with the non-endothelial artificial surfaces of the extracorporeal circuit causes hypercoagulability. This in turn can trigger a phenomenon of fibrinolysis with subsequent consumption of coagulation factors, platelet dysfunction and a massive inflammatory response, leading to bleeding [21, 22] . As a matter of fact, anticoagulant therapy is fundamental to prevent these serious problems and the level of anticoagulation required for thrombosis prevention depends on many factors. As shown in Table   3 , treatment with bivalirudin was applied as the first choice in the majority of patients in VV ECMO (79% of cases) and no longer as an alternative to heparin (used only in 21% of patients).

Although no recommendation exists on the use of direct thrombin inhibitor as primary anticoagulation in patients on ECMO, we preferred this strategy in this extremely critically ill population and we gathered positive experiences with direct thrombin inhibitor for patients treated with extracorporeal circuits [12] [13] [14] . Indeed, on one hand side direct thrombin inhibitor anticoagulant effect is more specific than heparin and can be easily monitored with aPTT, while on the on the other hand side low platelet count is frequently observed in critically ill patients [23] , and the risk of heparin induced thrombocytopenia is higher in patients on extracorporeal support.

Notably, transition from heparin to bivalirudin was accompanied by increase in survival rate (55% vs 31%, p=0.03) and reduced thrombocytopenia incidence in the bivalirudin group (69% vs 35%, p=0.003).Such results are in line with a recently published study on 295 VV ECMO patients, which documented higher 1 year survival rate, less circuit thrombotic events and decreased blood product administration in patients treated with bivalirudin compared to heparin [24] .

Furthermore, it is our practice also to administer intravenous short-acting beta-blockers during VV ECMO treatment. This innovative strategy has been introduced for the first time by our group in patients with refractory hypoxemia with high flow ECMO and high endogenous cardiac output with the aim of improving peripheral oxygenation and preliminary experience were encouraging [18, 19] .

Indeed, the ratio between V-V ECMO-oxygenated blood and the patients' venous blood can be raised by decreasing the patients' cardiac output with short acting beta blockers (time to peak effect 6-10 min, washout time 9 min) reducing recirculation amount.

Even though this practice is not commonly spread among ECMO centers, we believe that it may be of great clinical benefit for two reasons: first, tachycardia correction is associated with improved survival, at least in non-ECMO patients [25] , and beta-blockers have shown beneficial effect of bblockers on the septic heart [26] ; second, endogenous cardiac output reduction produces an increase in arterial PaO 2 in VV ECMO patients [18, 19] . Hypoxemia during ECMO may be ascribed mainly to the mixture between the blood fully oxygenated by ECMO with the patient's blood; the recirculation rate between the cannulae, and the inability of the native lung to provide further oxygenation together with the shunt because of the bronchial circulation that may worsen arterial PaO 2 . Therefore, the shunt between the blood fully oxygenated by ECMO and the patient's own venous blood can be modified in selected patients to provide clinical benefits [18] . We are aware that other strategies exist and may be applied to improve oxygenation during VV ECMO treatment, including change in cannulation approach, multiple cannulations or transition to VA ECMO: however, the feasibility and safety of our preliminary findings encourage, in our opinion, a trial with esmolol during VV ECMO in ARDS patients with refractory hypoxia and hyperdynamic circulation with high cardiac output, before embracing the more invasive maneuvers in critically ill unstable patients.

In addition, the single bilumen cannulation was adopted in more than half of the patients (55%) and became our standard of care since 2012. Indeed, we managed VV ECMO patients in order to put them in sponatenous breathing as soon as possible in order to avoid excessive work of breathing with the aim to preserve with the aim to preserve the best ventilation-perfusion match and reduce lung injury, reduce the need for sedatives and promote rehabilitation, oral feeding and recovery. In this clinical setting, bilumen cannulation was a key element, since this technique enabled early extubation in 32% of patients and a more practical and safer mobilisation of the patient before ECMO removal (25% mobilisation on one side and 15% in the armchair). Furthermore, it proved to be safe and easy to handle: cannulation at bedside under transesophageal echocardiography (TEE) guidance was successful in all patients and post-implantation chest X-Ray and bedside TEE enabled cannula position controls over days of VV ECMO support, especially in mobilized patients. No increased recirculation or need for proning and agiunctive pharmacological therapy were observed with this strategy.

Some limitations of this study should be acknowledged. First, the nature of the study is observational. However, conducting a randomized trial on ECMO is both clinically and ethically complex. As a matter of fact, the only 2 large randomized trials conducted on VV ECMO are the CESAR trial and the EOLIA trial [8, 9] . Despite these limitations, our study represents an important contribution in the analysis of the experience and outcomes of refractory ARDS ECMO VV patients, with significant effects in clinical practice. Second, some data are missing and couldn't be retrieved from record charts (especially pre ECMO parameters and some specific circuit related issues). This study also shows that the main cause of ARDS found in patients admitted for VV ECMO implantation in 2020 was attributable to Sars-Cov-2 infection (12 patients out of 14 from February to May 2020). This observation highlights the fact that we must be able to manage VV ECMO treatment not only as an established therapy for known pattern of ARDS, but also that we must ready to face outbreaks of new diseases with different patterns. For example, it has been highlighted that SARS-CoV-2 pneumonia should be considered a specific disease with particular phenotypes [27] . Although this input is extremely interesting, our study is underpowered to provide relevant information of this subgroup of patients and to provide comparisons with other patients' subgroups.

In conclusion, this study contributes to the complex debate about VV ECMO as a treatment in patients with severe ARDS who are refractory to conventional mechanical protective ventilation.

Our experience proved that treatment with VV ECMO is effective and might be life-saving in a relevant percentage of patients, thus confirming what recently observed in the same reality [11] .

Duration of extracorporeal support has impact on clinical outcome. The choice of medical therapies during VV ECMO treatment (anticoagulants above all) arguably has a crucial role to reduce complication and improve outcomes. 

Extracorporeal membrane oxygenation (ECMO) in patients with H1N1 influenza infection: a systematic review and meta-analysis including 8 studies and 266 patients receiving ECMO

Venovenous ECMO treatment, outcomes, and complications in adults according to large case series: A systematic review

Effect of extracorporeal membrane oxygenation transport on short-and long-term survival in patients with acute respiratory distress syndrome

Extracorporeal Membrane Oxygenation in Severe Acute Respiratory Failure: A Randomized Prospective Study

Extracorporeal Membrane Oxygenation for 2009 Influenza A (H1N1) Acute Respiratory Distress Syndrome

Extracorporeal Membrane Oxygenation | Kaplan's Cardiac Anesthesia

Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases

Conventional ventilatory support vs extracorporeal membrane oxygenation for severe adult respiratory failure

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

The Italian ECMO network experience during the 2009 influenza A(H1N1) pandemic: preparation for severe respiratory emergency outbreaks

Trend and pattern of 100 ARDS patients referred for VV ECMO treatment in a national referral center in North Italy over the last decade

Anticoagulation for critically ill cardiac surgery patients: is primary bivalirudin the next step?

Primary anticoagulation with bivalirudin for patients with implantable ventricular assist devices

Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study

Predicting mortality risk in patients undergoing venovenous ECMO for ARDS due to influenza A (H1N1) pneumonia: The ECMOnet score

Transfusion, and Mortality on Extracorporeal Life Support: ECLS Working Group on Thrombosis and Hemostasis

Cardiac support with IABP during venovenous ECMO for ARDS

β-Blockers to optimize peripheral oxygenation during extracorporeal membrane oxygenation: a case series

Esmolol administration in patients with VV ECMO: why not?

A meta-analysis of complications and mortality of extracorporeal membrane oxygenation

Tips and Tricks" Sulla Gestione Del Supporto Extracorporeo Alle Funzioni Vitali in Unità Di Terapia Intensiva Cardiologica

Therapeutic Interventions and Risk Factors of Bleeding during Extracorporeal Membrane Oxygenation

Prevalence and outcome of heparin-induced thrombocytopenia diagnosed under veno-arterial extracorporeal membrane oxygenation: a retrospective nationwide study

Comparison of Anticoagulation Strategies in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation: Heparin Versus Bivalirudin

Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial

Previous prescrip-tion of b-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis

COVID-19 pneumonia: ARDS or not?